HomeBusinessHealthcare Industry Stock NewsAbbvie (ABBV) To Acquire Immunogen (IMGN)

Abbvie (ABBV) To Acquire Immunogen (IMGN)

Abbvie (ABBV) is to acquire Immunogen (IMGN). Jenny Horne discusses this Biotech deal as the transaction values IMGN at $10.1B. ABBV is to acquire outstanding shares of IMGN for $31.26 per share in cash. This deal is expected to close in the middle of 2024 and the proposed transaction is expected to be accretive to EPS beginning in 2027. Tune in to find out more about the stock market today.

Market On Close

30 Nov 2023

SHARE

ON AIR
education
7:30 pm
Your First Trade
replay
12:00 am
Fast Market
REPLAY
1:00 am
Trading 360
REPLAY
2:00 am
Next Gen Investing
REPLAY
education
3:00 am
Your First Trade
REPLAY
3:30 am
Trading 360
REPLAY
4:30 am
Next Gen Investing
REPLAY
education
5:30 am
Your First Trade
REPLAY
6:00 am
Fast Market
REPLAY
7:00 am
Futures
8:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
3:30 pm
Market Overtime
4:00 pm
Trading 360
REPLAY
5:00 pm
Fast Market
REPLAY
6:00 pm
Next Gen Investing
REPLAY
7:00 pm
Market Overtime
REPLAY
ON AIR
education
7:30 pm
Your First Trade
REPLAY
8:00 pm
Trading 360
REPLAY
9:00 pm
Market Overtime
REPLAY
education
9:30 pm
Your First Trade
REPLAY
10:00 pm
Fast Market
REPLAY
11:00 pm
Trading 360
REPLAY

Get the Market Minute

Daily insights for every investor

coming soon

We are now

coming soon

We are now